LENVATINIB

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Differentiated Thyroid Cancer

Conditions

Differentiated Thyroid Cancer, Advanced Cancer

Trial Timeline

Mar 9, 2021 → May 27, 2026

NCT ID

NCT04321954

About LENVATINIB

LENVATINIB is a phase 2 stage product being developed by Eisai for Differentiated Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04321954. Target conditions include Differentiated Thyroid Cancer, Advanced Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03533361	Pre-clinical	Completed	—	—	Thyroid Cancer
NCT02211222	Pre-clinical	Completed	—	Jun 1, 2015	Differentiated Thyroid Cancer
NCT05901194	Phase 1/2	Active	Jul 10, 2024	Apr 1, 2027	Hepatocellular Carcinoma Non-resectable
NCT06138769	Phase 2	Active	Jul 20, 2023	Nov 1, 2027	Hepatocellular Carcinoma
NCT05171335	Phase 2	Recruiting	Jun 20, 2022	Dec 30, 2027	Hepatocellular Carcinoma
NCT05103904	Phase 2	Recruiting	Apr 19, 2022	Nov 4, 2026	Recurrent Hepatocellular Carcinoma
NCT04321954	Phase 2	Active	Mar 9, 2021	May 27, 2026	Differentiated Thyroid Cancer
NCT04297254	Approved	Completed	Feb 4, 2021	Jul 31, 2023	Carcinoma, Hepatocellular
NCT04447755	Phase 2	Completed	Jul 30, 2020	Feb 13, 2025	Relapsed or Refractory Solid Tumors
NCT04008082	Pre-clinical	Completed	May 14, 2019	Jan 28, 2022	Carcinoma, Hepatocellular
NCT03506048	Phase 2	Terminated	Jan 16, 2019	Jun 24, 2021	Differentiated Thyroid Gland Carcinoma
NCT03009292	Phase 1	Completed	Aug 6, 2018	Aug 27, 2021	Solid Tumor
NCT03663114	Pre-clinical	Completed	Jul 2, 2018	Feb 20, 2020	Carcinoma, Hepatocellular
NCT02846766	Phase 2	Withdrawn	Jul 1, 2018	Jun 1, 2021	Cancer
NCT03433703	Phase 2	Terminated	Apr 26, 2018	Jan 7, 2019	Carcinoma, Hepatocellular
NCT03573960	Approved	Completed	Apr 1, 2018	Sep 4, 2025	Thyroid Neoplasms
NCT03168074	Phase 2	UNKNOWN	Mar 28, 2017	Mar 28, 2021	Breast Cancer
NCT02953743	Phase 1	Completed	Sep 1, 2016	Dec 28, 2020	Unresectable Hepatocellular Carcinoma (HCC)
NCT02780310	Phase 2	Active	May 19, 2016	May 1, 2026	Adenoid Cystic Carcinoma
NCT02579616	Phase 2	Completed	Oct 23, 2015	Feb 27, 2019	Biliary Tract Cancer

Competing Products

20 competing products in Differentiated Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	33
Abemaciclib + Placebo	Eli Lilly	Phase 3	77
Lenvatinib + Placebo	Eisai	Phase 3	77
Lenvatinib	Eisai	Pre-clinical	23
Lenvatinib	Eisai	Phase 2	52
Selpercatinib Monotherapy	Eli Lilly	Phase 2	52
Selumetinib + Placebo + Radioactive Iodine Therapy	AstraZeneca	Phase 3	77
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	23
Everolimus + Sorafenib	Novartis	Phase 2	52
Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo	Novartis	Phase 3	77
PDR001	Novartis	Phase 2	52
Everolimus (Afinitor®)	Novartis	Phase 2	52
Sacituzumab govitecan	Gilead Sciences	Phase 2	51
sunitinib	Pfizer	Approved	84
Vandetanib (SAR390530) + Placebo	Sanofi	Phase 3	76
Thyrogen (thyrotropin alfa for injection)	Sanofi	Phase 3	76
Cabazitaxel	Sanofi	Phase 2	51
Larotrectinib monotherapy	Bayer	Phase 2	49

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved